biote Corp. (BTMD) AI Stock Analysis

biote Corp. specializes in medical practice-building within the hormone optimization sector. Founded in 2011 and based in Irvine, Texas, the company delivers a platform for Biote-certified practitioners to treat hormone imbalances. Its offerings include bioidentical hormone therapies, Biote-branded dietary supplements, and sterile pellet insertion kits for men and women. These tools and educational resources enable practitioners to deliver hormone replacement therapies safely and effectively while advancing patient care through ongoing research and platform development.

biote Corp. expanded revenue from $139.4M in FY2021 to a peak of $197.2M in FY2024 before revenue fell 2.5% to $192.2M in FY2025. Over the five years from FY2020 to FY2025, revenue grew at a CAGR of 10.5%. Gross margin widened steadily from 65.0% in FY2021 to 71.5% in FY2025, while operating margin rose to 18.5%. Net income reached $27.0M in FY2025 with diluted EPS of $0.59. For the trailing twelve months, revenue was $183.5M with a profit margin of 3.2%. However, for the quarter ending June 30, 2026, quarterly revenue fell 9.5% and quarterly earnings fell 83.8% year-over-year.

As of June 30, 2026, biote Corp. held cash and short-term investments of $11.2M compared to total debt of $128.6M, resulting in net debt of $117.5M. The current ratio stood at 1.43, total assets were $101.7M, and shareholders' equity was -$65.8M. In FY2025, the business generated operating cash flow of $35.2M and free cash flow of $30.2M. Cash utilization during FY2025 included $5.0M for capital expenditures, $3.4M for share buybacks, and $1.7M paid in dividends.

BTMD trades at a trailing P/E of 7.8x and a forward P/E of 5.2x, both well below the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. The company's price-to-sales multiple is 0.2x against the peer median of 4.1x, and its EV-to-EBITDA is 6.6x compared to 12.0x for peers. Over the past year, BTMD stock dropped 62.6%, substantially underperforming the S&P 500 (SPY), which gained 16.8%.

Wall Street coverage includes 4 Strong Buy ratings and 1 Hold rating, with no Buy, Sell, or Strong Sell recommendations. The mean price target is $2.61, representing an upside of 140.7% over the last close of $1.08 on October 16, 2026. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $177.9M and EPS of $0.35, marking an expected EPS decrease of 37.7%. biote Corp. has beaten EPS estimates in 2 of the last 4 quarters, with its next earnings report scheduled for November 4, 2026.

This page is an AI-written research summary of biote Corp. (BTMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BTMD income statement, BTMD balance sheet, BTMD key metrics, BTMD analyst forecast, BTMD chart. See the BTMD stock overview for the latest quote and news.